Four phase 1 trials to evaluate the safety and pharmacokinetic profile of single and repeated dosing of SCO‐101 in adult male and female volunteers

SCO‐101 (Endovion) was discontinued 20 years ago as a new drug under development against sickle cell anaemia. Data from the phase 1 studies remained unpublished. New data indicate that SCO‐101 might be efficacious as add‐on therapy in cancer. Thus, we report the results from the four phase 1 trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergmann, Troels K., Stage, Tore B., Stenvang, Jan, Christophersen, Palle, Jacobsen, Thomas A., Roest, Nicklas L., Vestlev, Peter M., Brünner, Nils
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539971/
https://www.ncbi.nlm.nih.gov/pubmed/32628359
http://dx.doi.org/10.1111/bcpt.13466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539971/
https://www.ncbi.nlm.nih.gov/pubmed/32628359
http://dx.doi.org/10.1111/bcpt.13466

Ejemplares similares